Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice

International Journal of Clinical Practice

Volumn 60, Issue 7, 2006, Pages 867-869

  Capps, N ^a  

^a PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

Audit; Ezetimibe; Fibrates; Lipids; Low density lipoprotein cholesterol; Statins; Total cholesterol

Indexed keywords

AZETIDINE DERIVATIVE; CHOLESTEROL; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGED; ARTICLE; BLOOD; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MEDICAL AUDIT; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33947424291     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2006.00958.x     Document Type: Article

References (11)

1. Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolaemia. Eur Heart J 2003; 24: 729-41. (Pubitemid 36458985)
2. Pearson TA, Denke MA, McBride PE et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolaemic patients: the Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. Mayo Clin Proc 2005; 80: 587-95. (Pubitemid 40628813)
3. Bosner MS, Lange LG, Stenson WF, Ostlund RE. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res 1999; 40: 302-8. (Pubitemid 29069805)
4. Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002; 106: 1943-8. (Pubitemid 35176299)
5. Altmann SW, Davis HR Jr, Zhu L et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004; 303: 1201-4. (Pubitemid 38233587)
6. Hegele RA, Guy J, Ban MR, Wang J. NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe. Lipids Health Dis 2005; 4: 16 (doi: 10.1186/1476-511X-4-16).
7. Jurado J, Seip R, Thompson PD. Effectiveness of ezetimibe in clinical practice. Am J Cardiol 2004; 93: 641-3. (Pubitemid 38293080)
8. Wierzbicki AS, Doherty E, Lumb PJ, Chik G, Crook MA. Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Curr Med Res Opin 2005; 21: 333-8.
9. Ziajka PE, Reis M, Kreul S, King H. Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe. Am J Cardiol 2004; 93: 779-80. (Pubitemid 38338578)
10. Wang J, Williams CM, Hegele RA. Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe. Clin Genet 2005; 67: 175-7. (Pubitemid 40287525)
11. Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905. (Pubitemid 40676570)